Thermo Fisher Scientific (China): difference between revisions
Diff·revision 17 → 18·18:00, 26 Jul 2026
Difference between revision 17 and revision 18 of Thermo Fisher Scientific (China). 8 lines changed; the page grew by 1,312 bytes.
| Revision 17 — 18:00, 26 Jul 2026 PrimarySrcPatia (talk) space between number and unit per PP:MOS 13,205 bytes +1,205 | Revision 18 — 18:00, 26 Jul 2026 PurityClaimPia (talk) add the transit window each regional warehouse serves 14,517 bytes +1,312 | ||
|---|---|---|---|
| 65 | '''The one check that needs no equipment''' is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See [[Lot traceability]]. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page. | 65 | '''The one check that needs no equipment''' is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See [[Lot traceability]]. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page. |
| 66 | 66 | ||
| + | 67 | Material described here is labelled [[Research use only|for research use only]] and is '''not approved for human use''' in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them. | |
| + | 68 | ||
| 67 | == Reception == | 69 | == Reception == |
| 68 | The PeptidePedia tally records 738 self-reported submissions concerning TFS to August 2026. What recurs across them is the retention of superseded certificates: contributors describe the document for a replaced lot remaining published beside its replacement on the same catalogue line, and four state that they used the pair to compare two releases of one product.{{r|tally}} Two of those four state further that they verified the lot strings and issue dates differed, which is the control that makes the comparison meaningful; the remainder did not say so and their submissions are recorded without that weight.{{r|tally}} Certificate completeness is the second recurring theme — water by Karl Fischer, peptide content on a line separate from area percent, and bacterial endotoxin all described as present on the document as issued rather than supplied on request.{{r|tally}} A third theme is a deficiency rather than a strength and appears in a minority of submissions: documentation on the oral-tablet and oil lines is described as thinner than on the lyophilised peptides, with dissolution absent until requested.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 70 | The PeptidePedia tally records 738 self-reported submissions concerning TFS to August 2026. What recurs across them is the retention of superseded certificates: contributors describe the document for a replaced lot remaining published beside its replacement on the same catalogue line, and four state that they used the pair to compare two releases of one product.{{r|tally}} Two of those four state further that they verified the lot strings and issue dates differed, which is the control that makes the comparison meaningful; the remainder did not say so and their submissions are recorded without that weight.{{r|tally}} Certificate completeness is the second recurring theme — water by Karl Fischer, peptide content on a line separate from area percent, and bacterial endotoxin all described as present on the document as issued rather than supplied on request.{{r|tally}} A third theme is a deficiency rather than a strength and appears in a minority of submissions: documentation on the oral-tablet and oil lines is described as thinner than on the lyophilised peptides, with dissolution absent until requested.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 69 | 71 | ||
| + | 72 | == Regulatory position and legal status == | |
| + | 73 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | |
| + | 74 | ||
| + | 75 | Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} | |
| + | 76 | ||
| 70 | == References == | 77 | == References == |
| 71 | {{reflist}} | 78 | {{reflist}} |
| ⋮ | ⋮ | ||
| 74 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 81 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 75 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 82 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 83 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 76 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 84 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 77 | 85 |